Antigen cross-presentation in dendric cells: From bench to bedside - 11/11/23
Abstract |
Cross-presentation (XPT) is an adaptation of the cellular process in which dendritic cells (DCs) present exogenous antigens on major histocompatibility complex (MHC) class I molecules for recognition of the cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, resulting in immunity or tolerance. Recent advances in DCs have broadened our understanding of the underlying mechanisms of XPT and strengthened their application in tumor immunotherapy. In this review, we summarized the known mechanisms of XPT, including the receptor-mediated internalization of exogenous antigens, endosome escape, engagement of the other XPT-related proteins, and adjuvants, which significantly enhance the XPT capacity of DCs. Consequently, various strategies to enhance XPT can be adopted and optimized to improve outcomes of DC-based therapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Receptor-mediated antigen uptake and antigen transportation improve XPT. |
• | The delayed antigen degradation and accelerated MHC I circulation enhance XPT. |
• | Adjuvants enhance antigen XPT in DCs through multiple mechanisms. |
• | Antigen XPT elevated by various approaches promotes anti-tumor responses. |
Keywords : Cross-presentation, Dendritic cells, MHC I, Antitumor
Plan
Vol 168
Article 115758- décembre 2023 Retour au numéro
Article précédent
- Potential of alisols as cancer therapeutic agents: Investigating molecular mechanisms, pharmacokinetics and metabolism
- Yinqi Wu, Xijun Wang, Le Yang, Shuyu Kang, Guangli Yan, Ying Han, Heng Fang, Hui Sun
- Chronic wound-related pain, wound healing and the therapeutic potential of cannabinoids and endocannabinoid system modulation
- Catherine R. Healy, Georgina Gethin, Abhay Pandit, David P. Finn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?